Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

Similar articles for PubMed (Select 20433379)

1.
2.

Neutrophil and platelet activation in equine recurrent airway obstruction is associated with increased neutrophil CD13 expression, but not platelet CD41/61 and CD62P or neutrophil-platelet aggregate formation.

Dunkel B, Rickards KJ, Werling D, Page CP, Cunningham FM.

Vet Immunol Immunopathol. 2009 Sep 15;131(1-2):25-32. doi: 10.1016/j.vetimm.2009.03.004. Epub 2009 Mar 20.

PMID:
19362377
3.

Phosphodiesterase isoenzymes in equine platelets and their influence on platelet adhesion.

Dunkel B, Rickards KJ, Page CP, Cunningham FM.

Am J Vet Res. 2007 Dec;68(12):1354-60.

PMID:
18052741
4.

Differential effects of phosphodiesterase inhibitors on platelet activating factor (PAF)- and adenosine diphosphate (ADP)-induced equine platelet aggregation.

Rickards KJ, Andrews MJ, Waterworth TH, Alexander GB, Cunningham FM.

J Vet Pharmacol Ther. 2003 Aug;26(4):277-82.

PMID:
12887610
5.

Platelet activation in ponies with airway inflammation.

Dunkel B, Rickards KJ, Page CP, Cunningham FM.

Equine Vet J. 2007 Nov;39(6):557-61.

PMID:
18065316
6.

In vitro and ex vivo effects of the phosphodiesterase 4 inhibitor, rolipram, on thromboxane production in equine blood.

Rickards KJ, Page CP, Lees P, Gettinby G, Cunningham FM.

J Vet Pharmacol Ther. 2003 Apr;26(2):123-30.

PMID:
12667182
8.

Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity.

Rose RJ, Liu H, Palmer D, Maurice DH.

Br J Pharmacol. 1997 Sep;122(2):233-40.

9.

Phosphodiesterase activity in neutrophils from horses with chronic obstructive pulmonary disease.

Rickards KJ, Page CP, Lees P, Cunningham FM.

Vet Immunol Immunopathol. 2000 Oct 31;76(3-4):319-30.

PMID:
11044563
10.

Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.

Feijge MA, Ansink K, Vanschoonbeek K, Heemskerk JW.

Biochem Pharmacol. 2004 Apr 15;67(8):1559-67.

PMID:
15041473
11.

Zardaverine: a cyclic AMP specific PDE III/IV inhibitor.

Schudt C, Winder S, Eltze M, Kilian U, Beume R.

Agents Actions Suppl. 1991;34:379-402. Review.

PMID:
1665311
12.

Allergen challenge alters lymphocyte phosphodiesterase activity in horses with heaves.

Rickards KJ, Page CP, Cunningham FM.

Pulm Pharmacol Ther. 2004;17(3):163-72.

PMID:
15123226
13.

Expression of surface platelet receptors (CD62P and CD41/61) in horses with recurrent airway obstruction (RAO).

Iwaszko-Simonik A, Niedzwiedz A, Graczyk S, Slowikowska M, Pliszczak-Krol A.

Vet Immunol Immunopathol. 2015 Mar 15;164(1-2):87-92. doi: 10.1016/j.vetimm.2015.01.002. Epub 2015 Jan 13.

PMID:
25665521
14.

Differential inhibition of equine neutrophil function by phosphodiesterase inhibitors.

Rickards KJ, Page CP, Lees P, Cunningham FM.

J Vet Pharmacol Ther. 2001 Aug;24(4):275-81.

PMID:
11555183
17.
19.

The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.

Hughes B, Howat D, Lisle H, Holbrook M, James T, Gozzard N, Blease K, Hughes P, Kingaby R, Warrellow G, Alexander R, Head J, Boyd E, Eaton M, Perry M, Wales M, Smith B, Owens R, Catterall C, Lumb S, Russell A, Allen R, Merriman M, Bloxham D, Higgs G.

Br J Pharmacol. 1996 Jul;118(5):1183-91.

20.

Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases.

Manns JM, Brenna KJ, Colman RW, Sheth SB.

Thromb Haemost. 2002 May;87(5):873-9.

PMID:
12038792
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk